News

Physicians are left to determine which treatments can offer patients best outcomes.

Classification criteria funded by the National Institutes of Health will facilitate clinical research for new therapies.

EyeGate Pharmaceuticals, Inc.'s lead product candidate is designed to treat dry eye disease-induced ocular surface inflammation.

Retrospective review highlights the sustained efficacy of combination procedure.

Amid pandemic, physicians and patients have embraced technology.

Update reduces complications

Stuart will enroll 150 volunteers in the study, which is being conducted with the support of Stuart's strategic partner and CRO, Ora Clinical. ST-100 is based on PolyCol, the company's synthesized polypeptide tissue reparative platform.

RGX-314 eyed by investigators as a therapeutic option for exudative AMD.

Lens option can correct for surgically induced astigmatism or an inaccurate position.

Physicians want to make sure they see each their patient frequently enough not to miss important changes in eye disease.

According to the company, more than 400 eyes of patients from 12 European countries have been fitted with the TECNIS Eyhance Toric II IOL, with surgeons surveyed noting that their patients are pleased with the results.

Researchers seek to identify new serological biomarkers that could better characterize Sjogren’s syndrome and overcome the limitations of traditional antibodies.

Option could prove to enhance safety for both patients and staff.

According to preliminary results, intranasally delivered ST266 is a safe treatment option.

Use of such procedures increased markedly in analysis of IRIS Registry Data.

UK physician notes a full systemic work-up needed to determine source of infection.

Nanoscope Therapeutics Inc. expects to advance the therapy by launching a late-stage Phase 2b trial this summer with gene therapy that delivers multi-characteristic opsin to retinal cells.

According to the company, preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gland injection of an adeno-associated virus containing the NGF gene produced statistically significant increase in NGF in tear film, as compared to placebo, as early as Day 7.

Study results show that aflibercept-treated eyes are protected.

Study results show the device offers an effective long-term option for patients.

Check out the latest cartoon!

More Americans have used and continue to use teleheath for mental health care. according to a recent online poll by the American Psychiatric Association.

Procedure can improve best-corrected visual acuity, enhancing quality of life for patients.

Therapeutic choices beneficial for patients may be available in 1 to 3 years.

A word from Chief Medical Editor Peter J. McDonnell, MD.

Virtual reality, home visual field testing offer new options for physicians.

ADVM-022 offers sharp decrease in treatment burden for patients with nAMD.

Technologies offer different approaches to different scenarios.